Compugen, Mayo Clinic to Hunt, Validate Biomarkers for Atherosclerotic Plaque | GenomeWeb
NEW YORK (GenomeWeb News) — Compugen and the Mayo Clinic plan to discover and validate biomarkers that could detect plaques linked to heart and brain diseases, the company said today.
 
Under the agreement, Compugen will retain exclusive commercialization rights to any products that result from the collaboration, which aims to find biomarkers for atherosclerotic plaques in coronary artery disease and in cerebrovascular disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.